Royalty Pharma
Tracked across 4 events · 32 articles · First seen Jul 07, 2026 · Last active Sep 05, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Royalty Pharma acquires a royalty interest in cliramitug, expanding its development-stage pipeline with a potential blockbuster drug.
Jul 22, 2026 · 7 articles
Business
Impact: Royalty Pharma announced the trial failure and expects to recoup its investment due to protective structuring, reiterating its 2030 target.
Sep 04, 2026 · 12 articles
Business
Impact: Royalty Pharma provides up to $500 million in R&D funding for TEV-408, sharing in potential future royalties.
Jul 07, 2026 · 7 articles
Tech
Impact: Royalty Pharma has a strategic funding agreement with Teva for TEV '408, and positive results may increase the potential value of its investment.
Sep 02, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Royalty Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard